Bagherieh Sara, Arefian Noor Mohammad, Ghajarzadeh Mahsa, Tafreshinejad Arash, Zali Alireza, Mirmosayyeb Omid, Safari Saeid
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Anesthesiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Curr J Neurol. 2023 Oct 7;22(4):249-254. doi: 10.18502/cjn.v22i4.14530.
Parkinson's disease (PD) is a progressive neuro-degenerative disease and olfactory dysfunction is considered as an important issue in these patients. The prevalence of olfactory dysfunction in patients with PD was reported variously in previous studies. Therefore, we designed this systematic review and meta-analysis to estimate the pooled prevalence of olfactory dysfunction in patients with PD. Two expert researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, references of the papers, and conference abstracts. The titles and abstracts of the potential studies were evaluated after deleting the duplicates. We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, mean disease duration, female/male, number with olfactory dysfunction, and name of the test. We evaluated the risk of potential bias by the Newcastle-Ottawa Quality Assessment Scale (adapted for cross-sectional studies). All statistical analyses were done using Stata software. To determine heterogeneity between the findings of included studies, inconsistency (I) was calculated. We applied random effect model when I was more than 50%. P-value less than 0.05 was considered significant. The literature search revealed 1546 studies; after deleting duplicates, 894 remained. Finally, twelve studies remained for meta-analysis. Studies were published between years of 2009 to 2021, the sample size of studies ranged between 30 and 2097, and the mean age ranged between 61 and 70 years. The pooled prevalence of olfactory dysfunction in patients with PD was estimated as 64% [95% confidence interval (CI): 44-84, I = 99.7%, P < 0.001]. The pooled prevalence of olfactory dysfunction using Sniffin's test was 67% (95% CI: 51-83) and using other tests was 60% (95% CI: 28-92). The results of this systematic review and meta-analysis showed that the pooled prevalence of olfactory dysfunction in patients with PD was 64% which should be considered by physicians.
帕金森病(PD)是一种进行性神经退行性疾病,嗅觉功能障碍被认为是这些患者的一个重要问题。先前的研究对PD患者嗅觉功能障碍的患病率报道不一。因此,我们设计了这项系统评价和荟萃分析,以估计PD患者嗅觉功能障碍的合并患病率。两名专家研究人员系统检索了PubMed、Scopus、EMBASE、Web of Science、谷歌学术、论文参考文献和会议摘要。删除重复项后,对潜在研究的标题和摘要进行评估。我们提取了有关参与者总数、第一作者、发表年份、原产国、平均年龄、平均病程、女性/男性、嗅觉功能障碍患者数量以及测试名称的数据。我们使用纽卡斯尔-渥太华质量评估量表(适用于横断面研究)评估潜在偏倚的风险。所有统计分析均使用Stata软件进行。为了确定纳入研究结果之间的异质性,计算了不一致性(I)。当I大于50%时,我们应用随机效应模型。P值小于0.05被认为具有统计学意义。文献检索共发现1546项研究;删除重复项后,剩余894项。最终,12项研究纳入荟萃分析。研究发表于2009年至2021年之间,研究样本量在30至2097之间,平均年龄在61至70岁之间。PD患者嗅觉功能障碍的合并患病率估计为64%[95%置信区间(CI):44-84,I = 99.7%,P < 0.001]。使用嗅觉测试时嗅觉功能障碍的合并患病率为67%(95%CI:51-83),使用其他测试时为60%(95%CI:28-92)。这项系统评价和荟萃分析的结果表明,PD患者嗅觉功能障碍的合并患病率为64%,医生应予以考虑。